Altimmune, Inc. (ALT)
| Market Cap | 414.08M |
| Revenue (ttm) | 3.45M |
| Net Income (ttm) | -83.82M |
| Shares Out | 39.74M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 670,903 |
| Open | 10.76 |
| Previous Close | 10.43 |
| Day's Range | 10.20 - 10.70 |
| 52-Week Range | 8.10 - 24.61 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 30.71 (+194.7%) |
| Earnings Date | Nov 10, 2021 |
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that i...
Financial Performance
In 2020, Altimmune's revenue was $8.19 million, an increase of 41.09% compared to the previous year's $5.80 million. Losses were -$49.04 million, 139.0% more than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Altimmune stock is "Strong Buy." The 12-month stock price forecast is 30.71, which is an increase of 194.72% from the latest price.
News
Altimmune to Present at Upcoming Investor and Scientific Conferences
GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be pres...
Altimmune to Present at Upcoming Investor Conferences
GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be pres...
Altimmune, Inc. (ALT) Reports Q3 Loss, Tops Revenue Estimates
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of -125.00% and 49.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial resul...
Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contac...
Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting vir...
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on ...
GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its ...
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
H.C. Wainwright said that Altimmune Inc (NASDAQ:ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients. However, shares dropped, which he sees primarily b...
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.
Why Altimmune Stock Is Under Pressure Today
Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.
See Why Altimmune Stock Plunged After Obesity Trial Data
Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. At 12 weeks, ...
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and O...
GAITHERSBURG, Md., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidu...
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 ...
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a...
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 9.09% and -93.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
GAITHERSBURG, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial resu...
Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Heads Into H2 With Stocks on a Streak
Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.
Why Altimmune Is Crashing Today
The company halts development on both a COVID-19 vaccine and a drug targeting the disease.
ALT in Freefall After Covid-19 Vaccine Trials Scrapped
Altimmune Inc (NASDAQ:ALT) is already taking its place as one of the worst performing stocks on the Nasdaq today, down 30.8% at $11 this morning, following news that the company dropped the development ...
Altimmune Stock Tanks On Double Bad News From COVID-19 Program
Altimmune Inc (NASDAQ: ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges. The Phase 1/2 trial for T-COVID, single-d...